The Cancer Letter

Inside information on cancer research and drug development

Black History MonthConversation with The Cancer Letter

University of Maryland’s Owonikoko: What it means to be a Black director of an NCI-designated cancer center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

A month after reporting to work in the top job at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Taofeek K. Owonikoko reflected on the obligations that come with being a Black director of an NCI-designated cancer center:

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Amy Lacey
VCU Massey Comprehensive Cancer Center
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Former chief medical and scientific officer, American Cancer Society
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Among cancer survivors, LGBTQ+ individuals report higher prevalence of chronic health conditions, disabilities, other limitations

Cancer survivors who identify as lesbian, gay, bisexual, transgender, queer, or anything other than straight and cisgender experience more chronic health conditions, disabilities, and other physical and cognitive limitations than non-LGBTQ+ cancer survivors; however, the prevalence of most conditions was highest among transgender or gender non-conforming individuals, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
Clinical Roundup

Oncology drugs approved post-2020 more likely to include postmarketing approaches to collecting data in underrepresented populations

Friends of Cancer Research characterized postmarketing requirements and commitments over the last decade. The perspective article, titled “An evaluation of novel oncology approvals with a PMR/C for assessing data in racial and ethnic populations underrepresented in premarket clinical trials,” provides insights into FDA’s expectations for representation of race and ethnicity in oncology clinical trials.
Byline
Amy Lacey
VCU Massey Comprehensive Cancer Center
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Former chief medical and scientific officer, American Cancer Society
Paul Goldberg
Editor & Publisher
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account